Quarterly report pursuant to Section 13 or 15(d)

Collaboration Revenue (Details Narrative)

v3.25.0.1
Collaboration Revenue (Details Narrative) - USD ($)
 3 Months Ended
Oct. 08, 2024
Dec. 31, 2024
Dec. 31, 2023
Sep. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Performance obligation   $ 1,000,000.0    
Collaboration revenue   1,000,000 $ 18,626  
Unbilled collaboration revenue   500,000  
License Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Proceeds for negotiate license agreement   1,000,000.0    
Alkem Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Proceeds for negotiate license agreement   1,000,000.0    
Collavorative arrangement right and obligation Company granted Alkem an exclusive license (with the right to sublicense) to research, develop, manufacture, import, export, market, use and commercialize pharmaceutical products containing its IL-6 (SON-080) asset (or any derivatives, fragments or conjugates thereof) (the “Compounds”) (such products, the “Products”) for the treatment of DPN (the “DPN Field”) and to manufacture, import, export, market, use and commercialize Products for the treatment of CIPN and autonomic neuropathy (together with the DPN Field, the “Fields”) in India. Except as provided for in the Alkem Agreement, the Company agreed not to develop, use, sell, offer or otherwise commercialize any Compounds or Products for use in the DPN Field in India during the term of the Alkem Agreement. The Company retains all rights to manufacture Compounds and Products anywhere in the world      
[custom:MilestonePayments-0]   $ 1,000,000.0